Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 135 Fluorouracil 129 Gemcitabine 114 Bevacizumab 111 Specimen Handling 101 Leucovorin 101 Capecitabine 87 Magnetic Resonance Spectroscopy 81 pembrolizumab 78 Cisplatin 74 Nivolumab 70 Irinotecan 68 Cetuximab 58 130-nm albumin-bound paclitaxel 58 durvalumab 57 Paclitaxel 57 Biopsy 55 atezolizumab 42 Radiotherapy 40 Albumin-Bound Paclitaxel 36 Taxes 35 Folfox protocol 34 Carboplatin 34 Drug Therapy 28 lenvatinib 27 sintilimab 26 dehydroftorafur 26 Radiation 26 Cyclophosphamide 26 tislelizumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Insulin × Gastrointestinal × 90 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡